Product Name:    Sorafenib

Synonyms:    Sorafenib free base for research;Sorafenib Free Base;Forafenib;Sorafenib free base(Bay43-9006);nexavar,sorafenib;BAY43-9006; NEXAVAR;Nexavar;Sorafenib-d4

CAS:    284461-73-0

MF:    C21H16ClF3N4O3

MW:    464.82

EINECS:    608-209-4

Product Categories:    Bay 43-9006;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate;Sorafinib;Molecular Targeted Antineoplastic;anti-neoplastic;Amines;Inhibitor;284461-73-0

Sorafenib is a small molecular inhibitor of several kinases involved in tumor angiogenesis and proliferation, including, but not limited to, Raf (IC50=12nM for Raf-1), VEGFR (IC50=90nM for VEGFR-2 and IC50=12nM for VEGFR-3), and platelet derived growth factor receptor (IC50=57nM for PDGFR-b). Specifically, sorafenib blocks tumor progression by inhibiting cellular proliferation that is dependent on activation of the MAPK pathway (Raf) and/or inhibiting tumor angiogenesis through VEGFR and/or PDGFR. While it may be effective in the treatment of a variety of tumors, the first approvable indication is for renal cell carcinoma. Overall, the drug appears to be well tolerated by the majority of patients at the 400 mg b.i.d. continuous dosing. As an inhibitor of multiple kinases vital for tumor progression, sorafenib may possess wide-spectrum antitumor properties and may emerge as an effective weapon against a variety of solid tumors.